{"filing":{"accession_number":"0001213900-26-104101","cik":"0001788028","ticker":"JSPRW","company_name":"Jasper Therapeutics, Inc.","form":"8-K","filing_date":"2026-09-28","report_date":"2026-09-23","primary_document":"ea0306856-8k_jasper.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1788028/000121390026104101/ea0306856-8k_jasper.htm"},"events":[{"id":35492,"run_id":32691,"accession_number":"0001213900-26-104101","anchor_item_number":"5.02","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.75,"summary":"Herb Cross resigned as Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer and Corporate Secretary effective October 9, 2026. While the filing also discloses interim appointments to fill these roles, the principal disclosed action is the departure of a named executive officer holding critical financial and governance positions. The departure of a CFO is material to investors assessing the registrant's financial leadership and continuity.","company_name":"Jasper Therapeutics, Inc.","ticker":"JSPRW","filing_date":"2026-09-28","form":"8-K","submitted_at":null,"items":[{"id":39557,"accession_number":"0001213900-26-104101","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"Herb Cross resigned as Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer and Corporate Secretary effective October 9, 2026. While the filing also discloses interim appointments to fill these roles, the principal disclosed action is the departure of a named executive officer holding critical financial and governance positions. The departure of a CFO is material to investors assessing the registrant's financial leadership and continuity.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-28T20:49:42.744162+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":39557,"accession_number":"0001213900-26-104101","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"Herb Cross resigned as Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer and Corporate Secretary effective October 9, 2026. While the filing also discloses interim appointments to fill these roles, the principal disclosed action is the departure of a named executive officer holding critical financial and governance positions. The departure of a CFO is material to investors assessing the registrant's financial leadership and continuity.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-28T20:49:42.744162+00:00","company_name":"Jasper Therapeutics, Inc.","ticker":"JSPRW","filing_date":"2026-09-28"}]}